Three of the four partner centres sell genetic screening, and they are selling different things under one word. This page separates them, because a broad predictive-risk gene panel, a targeted hereditary-disease panel and a personal-traits report are not the same product and do not carry the same weight.
KMI, Medione and Hanaro. Severance publishes none.
Its COMMON DISEASES program names a genetic test of 11 types; its other targeted programs name five each, for cardio-cerebrovascular disease or for common cancers.
A partner centre's price for a disease-risk prediction panel, and the same again for a personal-traits report. (≈$224)
KMI COMMON DISEASES, where the 11-gene panel is part of the programme rather than an add-on. (≈$745)
One week is the earliest an imaging slot can be held, and there is no referral step before it.
English report in your hands in about a week. You also get a consultation on preliminary findings on the day of the screening, before you leave.
Programme contents and prices from each partner centre's own foreigner-facing published list, read 2026-08-05: KMI Global and Hanaro Medical Foundation's English site. Standalone per-test prices are a Korean partner centre's 비급여 (non-covered) posting, the itemised list 의료법 제45조 requires a clinic to publish, read the same day. Scheduling and report turnaround are Meridiko's own operating figures, confirmed 2026-08-06, not a centre's published ones (https://global.kmi.or.kr/examination/foreigner_examination; https://en-mobile.hanaromf.com/program/prog01/prog01_01.jsp), measured 2026-08-05. Dollar figures are converted from each centre's won price at ₩1,342 = $1 (open.er-api.com, 2026-09-13). The won figure is the price; the pairing moves with the rate.
A hereditary-cancer NGS panel sequences named genes for pathogenic variants and is the only one of the three with established clinical action attached. A disease-risk prediction panel scores common variants for conditions like diabetes or hypertension. A personal-traits report covers things like caffeine metabolism and is entertainment with a laboratory attached.
None of them tells you that you will develop a disease. A negative hereditary-cancer panel does not remove your risk, and a high polygenic score is not a diagnosis. None of them replaces a family history taken properly by a doctor.
Suits: People with a strong family history of cancer, cardiomyopathy or early stroke, for whom a hereditary panel can change surveillance. Hanaro's Platinum is the only partner program that names its panels individually, which is what makes it assessable.
Should not have it: Anyone hoping for reassurance. These panels are better at raising questions than settling them, and a result that needs genetic counselling to interpret is a result you should not receive in a language you do not read fluently or with nobody to discuss it with.
A tumour-marker blood panel measures something in your blood today. A genetic panel measures something that has been true since birth. The first can change next year; the second will not, which is why it is worth doing once and worth doing properly.
Not carried as a matter of course by the bands this site prices. Each of KMI's targeted programmes includes a genetic test of its own, Medione's C. Premium Health Checkup includes predictive genetic testing and a personalised trait report, and Hanaro sells its DNA and pharmacogenomic panels as add-ons. Which genes are actually sequenced differs between them, so ask for the gene list rather than the word.
